title: Clinical inquiries. Does hypercoagulopathy testing benefit patients with DVT?
abstract: There is no evidence to suggest that testing for hypercoagulopathy benefits most patients with deep venous thrombosis (DVT). Nor has research established that thrombophilia test results improve the ability to predict recurrence better than clinical risk assessment alone. Testing may be warranted in patients younger than 50 years with idiopathic DVT or patients with recurrent episodes of thromboembolism to assess risk in other family members. A theoretical cost-benefit analysis demonstrates that testing for antiphospholipid antibody syndrome and homozygous factor V Leiden may be cost effective when comparing quality-adjusted life years in patients with idiopathic DVT.
authors.affiliation: Miami Valley Hospital Family Medicine Residency, Dayton, OH, USA.
authors.forename: Alisha
authors.initials: A
authors.lastname: Saultz
authors.forename: Erin Lindsay
authors.initials: EL
authors.lastname: Mathews
authors.forename: John W
authors.initials: JW
authors.lastname: Saultz
authors.forename: Dolores
authors.initials: D
authors.lastname: Judkins
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D003245:Consensus Statements as Topic; D006801:Humans; D019851:Thrombophilia / Q000175:diagnosis*; D020246:Venous Thrombosis / Q000097:blood* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants